Unbound MEDLINE

[Clinical isolates of Pseudomonas aeruginosa producers of extended spectrum ss-lactamases at a prívate institution in Córdoba.] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología [Rev Chilena Infectol] Journal article

 
Title[Clinical isolates of Pseudomonas aeruginosa producers of extended spectrum ss-lactamases at a prívate institution in Córdoba.]
Author(s)Piersigilli AL, Enrico MC, Bongiovanni ME, Bilbao LE, Martínez G, Ledesma EM 
InstitutionServicio de Bacteriología, Sanatorio Privado Aconcagua, Córdoba, Argentina.
SourceRev Chilena Infectol 2009 Aug; 26(4):331-5.
AbstractExtended spectrum p-lactamases (ESBL) are capable of inhibiting the action of extended spectrum cephalosporins and monobactams. The objective of this work is to describe six isolates of ESBL producing Pseudomonas aeruginosa, retrieved from intensive care patients. The susceptibility test was performed by diffusion. For the phenotypic detection of ESBL, the following was assessed: the difference between ceftazidime ceftazidime/clavulanic acid (CAZ-CAC) and the synergy between imipenem-ceftazidime (IMI-CAZ) and cefepime-ceftazidime/clavulanic acid -ceftazidime (FEP-CAC-CAZ). The presence of metallo-ss-lactamases (MBL) was discarded through the double disc imipenem-EDTA/mercaptoacetic-meropenem (IMI-EDTA/SMA-MER) method. Molecular characterization of ESBL was performed by polimerase chain reaction (PCR) with blaGES primers. Synergy IMI-CAZ was observed in the studied strains; ESBL type GES was confirmed in five of them. The strategic location of the discs and the evaluation of alert signáis for the detection of ESBL is essential, thus contributing to the correct recommendation of treatment in the clinical report.
Languagespa
Pub Type(s)English Abstract
Journal Article
PubMed ID19802399
  
Advertise on this site.